spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Alfacell 

 HSMN NewsFeed - 27 Feb 2014
Arno Therapeutics Appoints Lawrence A. Kenyon Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Jul 2010
K-V Pharmaceutical Company Announces the Election of New Independent Member to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jul 2008
Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
Biopharmaceuticals Distribution
 HSMN NewsFeed - 28 Apr 2008
Alfacell Announces Retirement of Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Apr 2008
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2008
Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement With BL&H for South Korea, Taiwan and Hong Kong
Biopharmaceuticals Distribution Oncology
 HSMN NewsFeed - 17 Jan 2008
Alfacell Appoints David Sidransky Chairman of the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jan 2008
Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 Nov 2007
Alfacell Appoints Lawrence A. Kenyon Chief Operating Officer and Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Oct 2007
Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2007
Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Sep 2007
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Aug 2007
Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jul 2007
Alfacell and US Pharmacia Announce ONCONASE(R) Distribution Agreement for Eastern Europe
Biopharmaceuticals Distribution
 HSMN NewsFeed - 18 Apr 2007
ONCONASE(R) has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2007
Researchers Identify Intracellular Pathway of Alfacell's ONCONASE(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell's ONCONASE(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Jan 2007
Alfacell Appoints David Sidransky M.D. as Vice Chairman and Lead Independent Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jan 2007
Alfacell Appoints Lawrence A. Kenyon as Executive Vice President, Chief Financial Officer and Corporate Secretary
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Dec 2006
Alfacell Corporation Files for U.S. Orphan Drug Designation for ONCONASE(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Dec 2006
Alfacell Corporation and GENESIS Pharma S.A. Announce Exclusive Licensing Agreement for ONCONASE in Southeast Europe
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Nov 2006
Study Reinforces Potential Utility of ONCONASE(R) in Non-Small-Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Nov 2006
Alfacell Corporation Announces Retirement of CFO, Robert D. Love
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Oct 2006
Further Analysis of Phase III Data Using CALGB and EORTC Paradigms Reinforces Survival Benefits of ONCONASE(R) for the Treatment of Patients with Mesothelioma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jun 2006
New Research Findings Published in National Academy of Sciences Journal Show Unique Promise of ONCONASE in the Prevention and Treatment of Mesothelioma and Lung Cancer Caused by Asbestos
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 May 2006
Alfacell Corporation To Launch New Program to Explore Potential of ONCONASE(R) to Prevent Mesothelioma
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 13

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 13 additional stories matching:
Alfacell
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.